2 completed, 2 terminated, 1 active not recruiting, 1 recruiting. 3 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 2, Active not recruiting 1 |
| Phase 2 | 3 | Terminated 2, Active not recruiting 1 |
Follow Ensoma: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of EN-374 Gene Therapy in Participants With X-Linked Chronic Granulomatous Disease EN-374 - X-Linked Chronic Granulomatous Disease | Phase 1 / Phase 2 | Active not recruiting | Ensoma | 15 | 2025-08-05 | 2026-08-21 |
| Prevalence of Antibodies and Cytokines in Participants With Chronic Granulomatous Disease Chronic Granulomatous Disease (CGD) | Recruiting | Ensoma | 60 | 2024-11-18 | 2026-08-17 | |
| Study of MGTA-145 and Plerixafor in Patients With Sickle Cell Disease MGTA-145, Plerixafor - Sickle Cell Disease | Phase 2 | Terminated | Ensoma | 1 | 2022-06-24 | 2025-07-25 |
| MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies MGTA-145, Plerixafor - Related Donors Donating PBSC to a Family Member, Healthy Donors | Phase 2 | Terminated | Ensoma | 7 | 2021-06-16 | 2024-11-06 |
| Study Assessing PK and Safety of MGTA-145 in Subjects With Normal Estimated GFR and Varying Degrees of Renal Impairment MGTA-145 - Healthy, Renal Insufficiency | Phase 1 | Completed | Ensoma | 23 | 2019-11-07 | 2024-01-11 |
| Study Assessing Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MGTA-145 in Healthy Volunteers as a Single Agent or in Combination With Plerixafor MGTA-145, plerixafor, Placebo - Healthy Volunteers | Phase 1 | Completed | Ensoma | 107 | 2019-04-22 | 2024-01-11 |
Granulomatous Disease, Chronic (2) · Anemia, Sickle Cell (1) · Leukemia, Myeloid, Acute (1) · Myelodysplastic Syndromes (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Renal Insufficiency (1)
plerixafor (3)
United States (6) · United Kingdom (2)
Ji Hyun Lee, MD, MPH (1) · Steven Devine, MD (1) · Will Savage, MD, PhD (1)